TG Therapeutics Inc (TGTX)

Return on equity (ROE)

Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019
Net income (ttm) US$ in thousands -14,364 95,686 41,197 12,672 -25,906 -175,654 -168,554 -198,335 -238,679 -288,498 -326,485 -348,100 -342,980 -344,506 -318,893 -279,381 -230,734 -205,501 -188,830 -172,870
Total stockholders’ equity US$ in thousands 192,157 177,568 160,109 160,502 164,769 40,453 27,433 58,587 100,481 129,035 170,386 237,153 311,517 383,130 445,285 519,350 170,658 194,227 -1,353 38,615
ROE -7.48% 53.89% 25.73% 7.90% -15.72% -434.22% -614.42% -338.53% -237.54% -223.58% -191.61% -146.78% -110.10% -89.92% -71.62% -53.79% -135.20% -105.80% -447.68%

September 30, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-14,364K ÷ $192,157K
= -7.48%

The return on equity (ROE) of TG Therapeutics Inc has displayed significant volatility over the past few quarters. The ROE has fluctuated between negative and positive values, indicating inconsistency in the company's ability to generate profit from shareholders' equity.

In the most recent quarter, ending September 30, 2024, the ROE was negative at -7.48%, reflecting a decrease from the previous quarter. This suggests that the company's profitability relative to its shareholders' equity deteriorated during this period.

Looking further back, the ROE had experienced a substantial improvement in the quarter ending June 30, 2024, reaching a relatively high value of 53.89%. This could indicate a period of strong profitability and efficiency in utilizing shareholders' equity to generate earnings.

However, the company has also encountered challenges in the past, as evidenced by extremely negative ROE figures in some quarters, such as the drastic declines in ROE in the quarters ending June 30, 2023, and March 31, 2023.

Overall, the fluctuating nature of TG Therapeutics Inc's ROE suggests inconsistency in the company's financial performance and efficiency in generating returns for its shareholders. Further analysis of the company's financial operations and strategies would be needed to understand the factors driving these fluctuations in ROE.


Peer comparison

Sep 30, 2024